Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
- Revenue in USD (TTM)40.33bn
- Net income in USD5.63bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
More ▼
Mergers & acquisitions
| Acquired company | ABT:NYQ since announced | Transaction value |
|---|---|---|
| Bigfoot Biomedical Inc | 1.92% | -- |
Data delayed at least 15 minutes, as of May 23 2024 00:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc | 19.50bn | 1.57bn | 37.40bn | 51.00k | 23.86 | 5.05 | 16.82 | 1.92 | 3.43 | 3.43 | 42.54 | 16.24 | 0.6013 | 5.45 | 4.51 | 382,254.90 | 5.01 | -- | 6.86 | -- | 40.69 | -- | 8.33 | -- | 0.8335 | 5.27 | 0.5491 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| DexCom Inc | 3.80bn | 639.30m | 52.03bn | 9.60k | 86.24 | 23.07 | 62.23 | 13.69 | 1.52 | 1.52 | 8.99 | 5.67 | 0.6337 | 2.93 | 4.71 | 396,020.80 | 10.66 | 8.30 | 14.97 | 10.50 | 63.25 | 65.90 | 16.82 | 14.14 | 2.53 | -- | 0.526 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Edwards Lifesciences Corp | 6.14bn | 1.41bn | 54.44bn | 19.80k | 38.83 | 7.65 | 34.94 | 8.86 | 2.33 | 2.33 | 10.11 | 11.82 | 0.6682 | 1.35 | 8.00 | 310,272.70 | 15.34 | 16.63 | 17.58 | 19.12 | 76.63 | 76.71 | 22.95 | 24.84 | 2.67 | -- | 0.0767 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Becton Dickinson and Co | 19.72bn | 1.36bn | 67.88bn | 73.00k | 49.99 | 2.66 | 18.58 | 3.44 | 4.70 | 4.54 | 67.74 | 88.32 | 0.3633 | 3.37 | 7.93 | 270,082.20 | 2.54 | 2.37 | 2.94 | 2.70 | 41.25 | 45.78 | 6.99 | 6.95 | 0.9705 | 6.91 | 0.4126 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Boston Scientific Corporation | 14.71bn | 1.77bn | 111.25bn | 48.00k | 63.18 | 5.58 | 37.34 | 7.56 | 1.20 | 1.20 | 9.99 | 13.56 | 0.4229 | 1.95 | 6.72 | 306,395.80 | 5.09 | 2.50 | 5.90 | 2.91 | 69.46 | 68.84 | 12.05 | 6.47 | 1.14 | 5.43 | 0.3449 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Medtronic PLC | 32.32bn | 4.20bn | 113.09bn | 95.00k | 27.00 | 2.19 | 16.38 | 3.50 | 3.15 | 3.15 | 24.27 | 38.95 | 0.3495 | 2.00 | 5.45 | 340,210.50 | 4.58 | 4.78 | 5.28 | 5.37 | 65.73 | 67.68 | 13.10 | 14.28 | 1.71 | 30.78 | 0.3263 | 72.49 | -1.45 | 0.8366 | -25.42 | -6.95 | 6.44 | 8.13 |
| Stryker Corp | 20.96bn | 3.36bn | 125.91bn | 52.00k | 37.77 | 6.57 | 28.67 | 6.01 | 8.75 | 8.75 | 54.57 | 50.33 | 0.55 | 1.61 | 6.27 | 403,134.60 | 8.82 | 6.60 | 10.60 | 7.84 | 64.01 | 63.99 | 16.03 | 13.13 | 0.9872 | -- | 0.4016 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Intuitive Surgical, Inc. | 7.32bn | 1.99bn | 142.63bn | 13.68k | 72.56 | 10.22 | 57.60 | 19.49 | 5.54 | 5.54 | 20.41 | 39.36 | 0.5068 | 2.19 | 7.13 | 535,134.60 | 13.88 | 12.42 | 15.39 | 13.83 | 66.43 | 67.60 | 27.38 | 26.31 | 4.61 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Abbott Laboratories | 40.33bn | 5.63bn | 179.11bn | 114.00k | 31.97 | 4.62 | 20.19 | 4.44 | 3.22 | 3.22 | 23.06 | 22.31 | 0.5514 | 2.67 | 6.39 | 353,736.80 | 7.70 | 7.72 | 9.60 | 9.39 | 55.25 | 56.73 | 13.96 | 14.39 | 1.11 | 22.29 | 0.272 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Thermo Fisher Scientific Inc | 42.49bn | 6.03bn | 225.26bn | 122.00k | 37.86 | 4.95 | 23.99 | 5.30 | 15.59 | 15.59 | 109.80 | 119.24 | 0.4432 | 4.69 | 4.56 | 348,295.10 | 6.26 | 7.79 | 7.43 | 9.11 | 40.40 | 44.94 | 14.13 | 16.76 | 1.33 | 17.55 | 0.4384 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
Data as of May 23 2024. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD
34.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 157.88m | 9.10% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 86.49m | 4.99% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 83.98m | 4.84% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 74.74m | 4.31% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 70.18m | 4.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 33.73m | 1.94% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 28.26m | 1.63% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 19.66m | 1.13% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 19.22m | 1.11% |
| Polen Capital Management LLCas of 31 Mar 2024 | 16.14m | 0.93% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
